Kura Oncology (NASDAQ:KURA) Cut to “Sell” at StockNews.com

StockNews.com cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a report issued on Monday morning.

Other equities analysts also recently issued reports about the company. JMP Securities lifted their target price on Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a research report on Wednesday, January 31st. HC Wainwright reissued a buy rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Wednesday, March 6th. Wedbush reissued an outperform rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Wednesday, February 28th. Finally, Mizuho assumed coverage on Kura Oncology in a research report on Friday, December 22nd. They set a buy rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $28.28.

Kura Oncology Stock Down 1.7 %

Shares of NASDAQ:KURA opened at $17.68 on Monday. The business has a 50-day moving average price of $20.83 and a 200 day moving average price of $15.12. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.50 and a beta of 0.85. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the company earned ($0.49) EPS. Sell-side analysts expect that Kura Oncology will post -2.35 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the sale, the chief operating officer now owns 21,602 shares in the company, valued at $384,515.60. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now owns 21,602 shares in the company, valued at $384,515.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas James Doyle sold 2,318 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the sale, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 96,919 shares of company stock worth $1,946,415. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale grew its holdings in Kura Oncology by 216.7% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock worth $1,343,000 after acquiring an additional 65,000 shares during the period. Bank of New York Mellon Corp grew its holdings in Kura Oncology by 10.9% during the third quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock worth $2,387,000 after acquiring an additional 25,677 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Kura Oncology by 18.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock worth $5,138,000 after acquiring an additional 86,141 shares during the period. Jupiter Asset Management Ltd. grew its holdings in Kura Oncology by 234.2% during the third quarter. Jupiter Asset Management Ltd. now owns 57,877 shares of the company’s stock worth $528,000 after acquiring an additional 40,560 shares during the period. Finally, Walleye Capital LLC grew its holdings in Kura Oncology by 220.4% during the third quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock worth $2,416,000 after acquiring an additional 182,221 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.